Join us for a panel discussion on:
• Board diversity progress
• Covid-19's impact on board governance and board diversity
• Importance of sponsorship and allyship in getting the first board seat
Disclaimer: This event may be recorded. If so, there is a possibility your image and or voice may be a part of that recording. If you do not wish for your image to be included please turn off your camera.
Annalisa Barrett is a Senior Advisor with the KPMG Board Leadership Center, where she plays a key role in the development of research and thought leadership and advises directors on emerging trends in corporate governance. She frequently speaks at conferences around the country addressing issues important to corporate directors, governance professionals, and investors. Barrett has been quoted on corporate governance and board practices in the New York Times, Bloomberg, and the Financial Times, and her research has been featured in the Wall Street Journal.
Prior to joining KPMG, Barrett was CEO of Board Governance Research LLC. Barrett was also a Senior Advisor for ValueEdge Advisors and Vice President and Senior Research Associate at The Corporate Library (now MSCI ESG Research). She previously was a Research Consultant in the Executive Compensation practice at Towers Perrin (now Willis Towers Watson) and a Tax Consultant in the Family Wealth Planning practice of Arthur Andersen.
In 2018, she was appointed to the California Insurance Diversity Task Force, which works to increase the diversity of insurance company boards. Barrett is also an adjunct professor at the University of San Diego School of Business, where she teaches graduate courses in corporate governance.
For over a decade, Barrett has served on the board of the Corporate Directors Forum (CDF), which provides governance education and peer networking for corporate directors. In 2019, she was selected by her fellow directors to receive the C. Hugh Friedman CDF Board Member of the Year award. In 2008, she was named a Millstein Rising Star in Corporate Governance by the Millstein Center for Global Markets and Corporate Ownership at Columbia Law School. She is a Scott M. Johnson Fellow of the US-Japan Leadership Program, a member of the International Corporate Governance Network, the Society for Corporate Governance, and the 30% Coalition. She holds an MBA with distinction from the Ross School of Business at the University of Michigan. She resides in San Diego, California with her husband and two children.
Consuelo Madere is the President and Founder of Proven Leader Advisory, LLC, a management consulting and executive coaching firm. She serves as an independent, non-executive board director for Nutrien (NYSE: NTR), the world’s largest provider of crop nutrients, inputs and services, playing a critical role in helping growers around the globe increase food production in a sustainable manner. She also serves as an independent, non-executive board director for Lindsay Corporation (NYSE: LNN), a global company focused on providing irrigation and infrastructure solutions to meet the needs of a growing population through development of innovative products and technology. In addition, Consuelo serves as an independent, non-executive board director for S&W Seed Company (NASDAQ: SANW), a supplier of proprietary seed including alfalfa, sorghum, sunflower, and stevia that supports the growing global demand for animal proteins and healthier consumer diets.
Consuelo is a member of the Dean’s Advisory Council of the Louisiana State University Ogden Honors College. She is also a member of the Latin Corporate Directors Association.
Consuelo Madere is a former Executive Officer of Monsanto, a leading global provider of innovative, sustainable agricultural solutions. She has over 30 years of domestic and global experience, spanning manufacturing, strategy, technology, business development, profit & loss responsibility and general management. With Monsanto she served in numerous key leadership positions with significant P&L responsibility across Europe, Middle East and Africa as well as Asia and key markets within the US business. She retired from Monsanto Company as Vice President of the company’s Global Vegetables and Asia commercial businesses and was a member of the CEO’s executive leadership team.
Her awards include Hispanic Executive “Best of the Boardroom”; Directors & Boards “Directors to Watch”; YWCA “Leaders of Distinction”; the St. Louis Business Journal’s “Most Influential People in Business”; Diversity Journal’s “Women Worth Watching”; and the Vista Magazine Corporate Achievement Award for “Hispanic Women in Business”. Her professional degrees include an MBA from the University of Iowa and a Bachelor of Science degree in Chemical Engineering from Louisiana State University. She is also certified by the National Association of Corporate Directors as a Board Leadership Fellow.
Lori Lyons-Williams is a proven Chief Commercial Officer with a strong track record of strategic and commercial success across biotech, pharmaceutical, and medical device markets, from prescription drugs to buy-and-bill and cash-pay products. In addition to full P&L responsibility in competitive markets, she has authored strategy and guided teams through both R&D pipeline advancement and business development deals.
As one of seven corporate officers on the executive team in her current role as Chief Commercial Officer of Dermira, a publicly traded biotech focused on medical dermatology, Lori is actively engaged in Investor Relations, including regularly presenting on quarterly calls and at the podium at roadshows and investor conferences. As the strategic, financial, and operational leader of the portfolio, she regularly interacts with the Dermira Board of Directors and coleads the Patient Value and Commercialization Committee. Over the course of her tenure, she has grown the commercial team from five employees to nearly 200 to meet significantly expanded demand for Dermira’s lead asset, QBREXZA®, which launched in October of 2018 and is estimated to generate $500 to $600 million in peak year sales. Her broad experience with equity, convertible, and traditional debt financing transactions includes guiding a small Dermira executive team through the company’s largest transaction to date, i.e., a $1-billion deal with RocheGenentech to acquire worldwide rights to lebrikizumab, a biologic under development for atopic dermatitis. (Although the company has not provided specific guidance, lebrikizumab is expected to be a blockbuster when it reaches peak sales.)
Previously, as the VP of Sales and Marketing at Allergan, Lori built what became one of the company’s fastest growing business units, i.e., the urology franchise, which generated more than 50% revenue growth during her tenure. As a key member of both the Commercial and the Operational leadership teams at Allergan, she led three major launches for pharmaceutical products that currently generate over $600 million in annual revenues (ACZONE® in acne; BOTOX® in neurogenic detrusor overactivity; BOTOX® in overactive bladder).
Under Lori’s leadership as CCO, Dermira stock saw significant jumps in 2019 alone. Most notably, she was a key player on the deal that positioned Dermira’s core assets to the global pharmaceutical giant, Eli Lilly as part of the January 2020 acquisition, with the development expertise and commercial infrastructure to take clinical stage lebrikizumab to market and drive the growth of the marketed Qbrexza.
She currently serves as Independent Director on the Board of Five Prime Therapeutics (NASDAQ: FPRX), a clinicalstage biotech focused on the discovery and development of protein therapeutics in immuno-oncology, and as Vice Chair, Board Director for the National Association of Continence. She previously served as Board Director at Girls Inc of Orange County and the Orange County Business Council. In addition to serving as a featured speaker and panelist at numerous industry events advocating gender equity in the workplace, she founded Women in Leadership at Allergan. Lori holds an MBA from the Carlson School of Management at the University of Minnesota and a BA from Virginia Tech.
Matthew Fust is an advisor to life sciences companies, executive teams and investors. He is a director of Atara Biotherapeutics, Crinetics Pharmaceuticals and Ultragenyx Pharmaceutical, an advisor to Out Leadership/Quorum, and a mentor for the Women in Bio Boardroom Ready program. From 2009 through 2013, Matthew was CFO of Onyx Pharmaceuticals. He previously served as CFO of Jazz Pharmaceuticals (2003 – 2008), CFO of Perlegen Sciences (2002 – 2003), and CFO of ALZA Corporation, where he was an executive from 1996 - 2001. Matthew previously worked in the healthcare strategy consulting practice at Andersen Consulting (now Accenture). He holds an undergraduate degree from the University of Minnesota and an M.B.A. from the Stanford University Graduate School of Business.
- Members: Free
- Limited Free Guest Registration (Non-member)*: $30
*To access the Member rate, click here to purchase a WIB membership.
Note: Our webinar will take place at GoToWebinar. After you complete registration you will receive a confirmation e-mail that includes a link to register at GoToWebinar. Please be sure to register at GoToWebinar so you receive your join link